MACULAR ISCHEMIA ASSOCIATED WITH IMATINIB MESYLATE THERAPY FOR CHRONIC MYELOID LEUKEMIA

Abstract

Imatinib mesylate may be associated with ischemic maculopathy that can severely compromise vision. It may be necessary for patients receiving this therapy to be monitored for associated visual symptoms and funduscopic abnormalities.